|FOR IMMEDIATE RELEASE||Contact:||Renae Neumann, Marketing Manager|
ERS Partners with HLA-Global to Launch
NLP Reportability Service for Cancer Registries
ERS, the leading innovator in cancer registry and analytics services partners with HLA-Global to offer new Cancer Reportability Service to US Cancer Registry market
CINCINNATI, OHIO, June 4, 2021 — ERS, the industry’s leading cancer registry solution provider, has been providing solutions to the cancer registry field since 1989 and currently has over 700 cancer centers utilizing their solutions and services nationally. Through this strategic partnership with HLA-Global, ERS will be launching a new service that will address a key area of need for cancer registries. This service, the ERS Cancer Reportability Service, will leverage HLA-Global’s award winning Clinical NLP technology to automate the effort-intensive casefinding process.
“We’re thrilled to announce our partnership with HLA-Global,” said Rohit Nayak, CEO of ERS. “They have the perfect mix of expertise with both nuances of cancer registry standards as well as proven NLP technologies necessary to provide a practical, cost-effective solution for case finding.” HLA-Global has been servicing a range of customers in the oncology space for over 10 years, including several central registries with accuracies in real-life production of 99.84% on more than 600,000 records, as reported by one of the USA’s largest cancer registries.
Most agree that cancer registries typically spend 10 – 15% of their FTE budget on manual case finding. “Providing the necessary automation to address this key need will allow Tumor Registrars to spend time on collating the important clinical attributes of the abstract – a task that has become increasingly difficult with the increased demands for registry reporting,” said Dr. Frederick Greene, ERS’s Chief Medical Officer. “In the final analysis, the goal is far greater than just timely, accurate reporting. Making it viable for researchers and clinicians alike to leverage this dataset and ultimately impact the patient’s care journey is where we’re headed,” added Dr. Greene.
“Our partnership with ERS fulfills one of our key objectives to make our technology universally accessible to all cancer centers nationally,” said Professor Jon Patrick, Founder and CEO of HLA-Global and the world-leading Clinical NLP expert. ERS will incorporate HLA-Global’s Clinical Language NLP solution into a new service that will seamlessly integrate with ERS’s widely used CRStar cancer registry solution. This new service is expected to be commercially available to all customers in Q4 2021 – after operationalizing with a few customers prior. “There is no question there is a need for this technology, and ERS’s national footprint provides us the ideal platform for a diverse user audience,” added Jon Patrick.
The two companies are also collaborating on a new add-on capability that will build upon the Reportability service. This service will use HLA-Global’s Content Extraction and Inferencing capabilities to determine a range of cancer staging attributes, further extending the benefit for CTRs during their abstracting process.
Health Language Analytics Global (HLA-Global) is a world-leading Clinical Natural Language Processing (CNLP) company that specializes in applying Computational Linguistics combined with Artificial Intelligence methods to the processing of clinical documents. It’s award-winning platform, HORIZON, is deployed across a range of state and federal health agencies, cancer registries, hospitals, and research organizations in the USA and Australia.
Learn more about HLA-Global at www.hla-global.com
About ERS, Inc.
With more than 30 years of proven results in cancer registry solutions, ERS, Inc. provides distinctive cancer registry compliance and informatics services that enable customers to achieve and exceed their cancer center clinical and business objectives with a goal of improving cancer care for every patient. As the industry’s first true cloud-based offering with innovative abstracting and case-finding capabilities, ERS’s CRStar offering empowers both individual cancer centers and large enterprise health systems to achieve their full potential by meeting and exceeding increasing regulatory, accreditation and quality reporting requirements while also providing insights for enhancing cancer program management.
Learn more about ERS at www.mycrstar.com
If you would like more information about this topic, please contact Renae Neumann.